Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

LIPOSOME COMPANY, LIPOSOME TECHNOLOGY PLANNED MERGER IS OFF

Executive Summary

LIPOSOME COMPANY, LIPOSOME TECHNOLOGY PLANNED MERGER IS OFF; the combination would have created a single corporation named Liposome Companies. In a May 24 press release, the companies announced their "decision to terminate their previously announced merger agreement." The companies originally announced the definitive merger agreement on Feb. 13. At the time, the merger between the oldest liposome R&D firms -- both were founded in 1981 -- was heralded as the beginning of a possible trend of consolidation among existing biotechnology companies. The merger was canceled despite a good fit between the companies' respective research efforts. In the only instances of overlap, both are developing liposomal formulations of the antifungal amphotericin B and doxorubicin; however, the companies have not entered into competing partnership agreements for those products.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS015665

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel